Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Natco Pharma shares jump 4% amid weak broader markets; here' why
Shares of Natco Pharma Ltd surged nearly 4.35 per cent to Rs 1,413.45 on Monday, commanding a total market capitalization close to Rs 25,000 crore.
Here's why Natco Pharma share price gained over 4% on October 7; details
Natco Pharma share rose after the company announced that Mylan Pharmaceuticals Inc & Novo Nordisk have reached a settlement of the US patent litigation related to generic Ozempic (Semaglutide)
Natco Pharma shares rise 4% on settlement order in US patent case over generic Ozempic
The strong up move was seen in the stock price with the scrip touching the day's high of Rs 1,408.70 per share on the NSE, rising 4 percent.
Natco Pharma shares gain after settlement in US patent litigation on generic Ozempic
Mylan Pharmaceuticals Inc and Novo Nordisk, the original patent holder for Ozempic, have reached a settlement in the US patent litigation concerning the drug, Natco Pharma informed the stock exchanges in a filing.
Natco Pharma soars after Mylan settles Ozempic patent dispute
Natco Pharma rose 3.39% to Rs 1400.60 after the company announced a settlement in the U.S. patent litigation for generic Ozempic.
Settlement Reached in Ozempic Patent Battle
NATCO Pharma Ltd announced that Mylan Pharmaceuticals Inc has settled a lawsuit with Novo Nordisk in the US concerning the generic version of Ozempic—a medication used for controlling blood sugar and weight loss.
Natco Pharma settles US patent case over generic Ozempic
According to data from the BSE index, the stock has achieved multibagger gains over the last two years, climbing 122.04%.
Mylan and Novo Nordisk settle US generic Ozempic dispute, Natco Pharma poised for market entry
Mylan and Novo Nordisk have reached a confidential settlement over the generic version of Ozempic, with Natco Pharma holding Sole First-to-File (FTF) status for multiple strengths of Ozempic and Wegovy.
Natco Pharma partner Mylan settles patent litigation with Novo Nordisk over generic Ozempic in US
Hyderabad: NATCO Pharma Limited has announced that its partner Mylan Pharmaceuticals Inc. and Novo Nordisk have reached a settlement of the U.S. patent litigation related to generic
Mylan Settles Patent Suit with Novo Nordisk over Generic Ozempic
Mylan Pharmaceuticals Inc. and Novo Nordisk have reached a settlement in the US over a patent infringement lawsuit regarding generic Ozempic, a drug used for blood sugar and weight loss.
FiercePharma
2h
Amid GLP-1 craze, Novo and Mylan ink patent settlement in Ozempic case
With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their ...
3h
on MSN
Stock market update: Nifty Pharma index falls 0.51%
The Nifty Pharma index closed on a negative note on Monday. Shares of Natco Pharma Ltd.(up 3.53 per cent), Glenmark ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Trending now
Madonna's brother dies
Ring ceremony canceled
Fans throw objects on field
American sentenced in RU
Bear w/ 3 cubs attacks man
2 boys arrested for assault
Canyoneering fall death
Father-son duo make history
Win Nobel Prize in medicine
Another top aide resigns
SCOTUS new term begins
ISR October 7 anniversary
FAA authorizes Oct 7 flight
Novelist Robert Coover dies
More troops to aid recovery
US, UK climbers rescued
Synagogue threats arrest
Hamas strikes Tel Aviv
Milton becomes Category 4
Mexican mayor assassinated
Trump's Wisconsin rally
Antisemitic incidents surge
Wins China Open final
Man sets self on fire in DC
Names 21 new cardinals
Catches fire while landing
Pereira defeats Rountree
Bans pagers, walkie-talkies
Man charged for threats
Related topics
Ozempic
Mylan
Feedback